MX2023005763A - Composiciones y metodos para la administracion dermica profunda de farmacos. - Google Patents

Composiciones y metodos para la administracion dermica profunda de farmacos.

Info

Publication number
MX2023005763A
MX2023005763A MX2023005763A MX2023005763A MX2023005763A MX 2023005763 A MX2023005763 A MX 2023005763A MX 2023005763 A MX2023005763 A MX 2023005763A MX 2023005763 A MX2023005763 A MX 2023005763A MX 2023005763 A MX2023005763 A MX 2023005763A
Authority
MX
Mexico
Prior art keywords
methods
compositions
drug delivery
deep dermal
dermal drug
Prior art date
Application number
MX2023005763A
Other languages
English (en)
Inventor
David W Osborne
Babak N Tofig
Original Assignee
Arcutis Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcutis Biotherapeutics Inc filed Critical Arcutis Biotherapeutics Inc
Publication of MX2023005763A publication Critical patent/MX2023005763A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composiciones farmacéuticas para la administración tópica de un fármaco a la unidad pilosebácea y métodos para la administración de éstas; como se divulga en la presente, los inventores de la presente invención han hecho el sorprendente descubrimiento de que las composiciones farmacéuticas que comprenden pequeñas partículas de un ingrediente farmacéutico activo pueden administrarse a la unidad pilosebácea; la composición farmacéutica puede comprender SHR0302 o espironolactona como ingrediente farmacéutico activo.
MX2023005763A 2020-11-17 2021-11-16 Composiciones y metodos para la administracion dermica profunda de farmacos. MX2023005763A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063114887P 2020-11-17 2020-11-17
US202163221349P 2021-07-13 2021-07-13
PCT/US2021/059487 WO2022108913A1 (en) 2020-11-17 2021-11-16 Compositions and methods for deep dermal drug delivery

Publications (1)

Publication Number Publication Date
MX2023005763A true MX2023005763A (es) 2023-05-29

Family

ID=78844577

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2023005759A MX2023005759A (es) 2020-11-17 2021-11-16 Composiciones y metodos para suministro de farmaco dermico profundo.
MX2023005763A MX2023005763A (es) 2020-11-17 2021-11-16 Composiciones y metodos para la administracion dermica profunda de farmacos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2023005759A MX2023005759A (es) 2020-11-17 2021-11-16 Composiciones y metodos para suministro de farmaco dermico profundo.

Country Status (9)

Country Link
US (4) US11628177B2 (es)
EP (2) EP4247336A1 (es)
JP (2) JP2023550364A (es)
KR (2) KR20230144002A (es)
AU (2) AU2021381899A1 (es)
CA (2) CA3198046A1 (es)
IL (2) IL302861A (es)
MX (2) MX2023005759A (es)
WO (2) WO2022108913A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023086471A1 (en) * 2021-11-11 2023-05-19 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of spironolactone for deep dermal drug delivery

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3013012A (en) 1960-12-22 1961-12-12 Searle & Co Alkanoylthio-17alpha-carboxyethyl-17beta-hydroxyandrosten-3-one lactones
US4837211A (en) 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
FR2787322B1 (fr) 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
EP2099420B8 (en) 2006-11-17 2017-03-15 PharmaSol GmbH Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2011110930A2 (en) * 2010-03-10 2011-09-15 Lupin Limited Rifaximin ready-to-use suspension
WO2012053014A2 (en) 2010-10-21 2012-04-26 Cadila Healthcare Limited Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene
WO2013014680A1 (en) 2011-07-28 2013-01-31 Cadila Healthcare Limited Method for treatment of pain and inflammation
JP6075736B2 (ja) 2011-12-21 2017-02-08 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピロール−６員ヘテロアリール環誘導体、その合成法およびその医薬用途
WO2014194741A1 (zh) 2013-06-07 2014-12-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐及其制备方法
GB201402448D0 (en) * 2014-02-12 2014-03-26 Buzzz Pharmaceuticals Ltd Novel formulation
CN105566327A (zh) 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
PT3216790T (pt) 2014-11-05 2019-11-19 Jiangsu Hengrui Medicine Co Forma cristalina de bissulfato inibidor de jak cinase e um seu método de preparação
BR112017020358A2 (pt) * 2015-03-23 2018-07-17 Biopharmx Inc composição farmacêutica de tetraciclina para uso dermatológico
EP3417861B1 (en) 2016-02-19 2020-09-23 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof
EP3658190A1 (en) * 2017-07-26 2020-06-03 FTF Pharma Private Limited Liquid dosage forms of imatinib
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
TWI717658B (zh) * 2017-11-20 2021-02-01 大陸商江蘇恒瑞醫藥股份有限公司 局部給藥的藥物組合物及其製備方法
EP3810144A4 (en) * 2018-06-04 2022-08-17 Chemistryrx TOPICAL HAIR GROWTH STIMULATING COMPOSITIONS

Also Published As

Publication number Publication date
EP4247491A1 (en) 2023-09-27
US11628177B2 (en) 2023-04-18
KR20230142449A (ko) 2023-10-11
IL302867A (en) 2023-07-01
JP2023550364A (ja) 2023-12-01
MX2023005759A (es) 2023-05-29
WO2022108913A1 (en) 2022-05-27
US20220152061A1 (en) 2022-05-19
KR20230144002A (ko) 2023-10-13
US20230226083A1 (en) 2023-07-20
AU2021381899A1 (en) 2023-07-06
CA3197815A1 (en) 2022-05-27
JP2023550363A (ja) 2023-12-01
IL302861A (en) 2023-07-01
EP4247336A1 (en) 2023-09-27
AU2021383606A1 (en) 2023-06-29
WO2022108911A1 (en) 2022-05-27
CA3198046A1 (en) 2022-05-27
US20230414511A1 (en) 2023-12-28
US20220152033A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
WO2018213582A8 (en) COMPONENTS WITH HIGH API LOAD
GB0814302D0 (en) Compounds and methods
WO2004105694A3 (en) Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
PH12020550341A1 (en) Niraparib formulations
MX2009007742A (es) Formulaciones farmaceuticas multi-fasicas de farmacos pobremente solubles en agua para una biodisponibilidad oral de variabilidad alimentada/en ayunas reducida y mejorada.
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
JP2016505050A5 (es)
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
EA202191130A1 (ru) Фармацевтическая композиция для лечения апластической анемии
MY191712A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
WO2011014009A3 (ko) 신규 이치환된 페녹시아세틸계 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 다약제내성 억제용 약학적 조성물
MX2023001572A (es) Formas farmaceuticas sólidas de palbociclib.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
PH12020551547A1 (en) Pharmaceutical preparation
MX2020006886A (es) Sistema para suministro de medicamento.
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
RU2560518C1 (ru) Средство, обладающее лимфокинетической активностью
MXPA06000760A (es) Composicion farmaceutica estable de carisoprodol y meloxicam.
JP5299449B2 (ja) 外用剤組成物
AU2019203288A1 (en) Process for preparing pharmaceutical compositions resulting in reduction in overall fill volume for use with soft gelatin formulations